Current trends in onychomycosis therapy: A literature review

Mount Sinai Journal of Medicine

Volumn 64, Issue 6, 1997, Pages 399-405

  Hecker, David ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Fluconazole; Griseofulvin; Itraconazole; Ketoconazole; Onychomycosis therapy; Terbinafine

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LIVER TOXICITY; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; RASH; REVIEW; TOPICAL DRUG ADMINISTRATION;

ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 0030669305     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Samman PD, Fenton DA, editors. The nails in disease. 2nd ed. Chicago: Yearbook Medical Publishers; 1986, p. 6.
2. Malawista SE, Sato H, Bensch KG. Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science 1968; 160:770-772.
3. Kaden R. Klinische und mykologische Nachuntersuchungen griseofulvinbehandelter Onychomykosen. Mycopathologia 1964; 25:351-360.
4. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; 3:464-468.
5. Korting HC, Schafer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37(10):2064-2068.
6. Robertson MH, Rich P, Parker F, Hanifin JM. Ketoconazole in griseofulvin-resistant dermatophytosis. J Am Acad Dermatol 1982; 6:224-229.
7. Galimberti R, Negroni R, Iglesia de Elias Costa MR, Casala AM. The activity of ketoconazole in the treatment of onychomycosis. Rev Infect Dis 1980; 2:596-598.
8. Knight TE, Shikuma CY, Knight J. Ketoconazole induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 251:398-400.
9. Stricker BA, Black APR, Bronkhorst FB, et al. Ketoconazole associated hepatic injury. J Hepatol 1986; 3:399-406.
10. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988; 32:1-8.
11. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128:909-910.
12. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3:115-117.
13. Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995; 88(12):1217-1220.
14. Grant SM, Clissold SP. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39:877-917.
15. Hay RJ. Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions. J Am Acad Dermatol 1993; 29(1):S50-S54.
16. Hanifin JM, Tofte SJ. Itraconazole therapy for recalcitrant dermatophyte infections. J Am Acad Dermatol 1988; 18:1077-1080.
17. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: Open and double-blind studies. Acta Derm Venereol 1990; 70:137-140.
18. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole of griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30(8):586-589.
19. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail: New implications for treatment in onychomycosis. J Am Acad Dermatol 1992; 26:731-735.
20. De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis: A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132(1):34-41.
21. Lavrijsen AO, Balmus KJ, Nugteren-Huying WM, et al. Hepatic injury associated with itraconazole. Lancet 1992; 340:251-252.
22. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304:1151-1153.
23. Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992; 26:956-960.
24. Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: A multicenter comparison of cure and relapse rates with 1-and 4-week treatment regimens. J Am Acad Dermatol 1993; 28:648-651.
25. Van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl 39:36-39.
26. Villars W, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 Suppl 39:61-69.
27. Goodfield MJD, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger-and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121:753-757.
28. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126 Suppl 39:40-46.
29. Villars W, Jones JC. Clinical efficacy and tolerability of terbinafine (Lamisil) - A new topical and systemic fungicidal drug for treatment of dermatomycoses. Rev Infect Dis 1989; 14:124-127.
30. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis of onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl 43:32-34.
31. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995; 311:919-922.
32. Pierard GE, Arrese JE, De Doncker P, Pierard-Franchimont C. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34(2 Pt 1):273-277.
33. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989; 32(8):609-619.
34. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989; 14:101-103.
35. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 Suppl 39:28-32.
36. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29(1):S37-S41.
37. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186:59-61.
38. Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazols in the management of onychomycosis. Br J Dermatol 1988; 119:359-366.